CLINICAL TRIALS PROFILE FOR PENTAGASTRIN
✉ Email this page to a colleague
All Clinical Trials for PENTAGASTRIN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00164788 ↗ | A Comparison of Gastric pH Control With High Dose Intravenous or Oral Esomeprazole | Terminated | Chinese University of Hong Kong | Phase 2 | 2004-07-01 | The investigators hypothesize that high dose esomeprazole 80mg given as a bolus, followed by 8mg/h would render gastric pH near neutral and that pH control with esomeprazole given in such a high dose either intravenous or orally is identical. |
| NCT00284700 ↗ | Is Helicobacter Pylori Infection a Cause or Treatment Failure of Iron Deficiency Anemia in Children in Bangladesh? | Completed | International Centre for Diarrhoeal Disease Research, Bangladesh | N/A | 1997-12-01 | Helicobacter pylori is recognized as a major gastrointestinal pathogen in developing countries. This microorganism infects up to 60% of children less than five years in those countries and is strongly associated with chronic gastritis and peptic ulcer disease in children and adults. The progression of gastritis to atrophy often leads to decreased gastric acid output, which is a well-known risk factor for anemia. Gastric acid is essential for increasing the bioavailability and absorption of non-heme dietary iron, the most important source of iron in developing countries. Numerous reports suggest that iron malabsorption secondary to low gastric acid output is a problem in developing world countries. It has been further observed that iron deficiency anemia is resistant to iron therapy particularly in these countries. In a recently completed study we observed an association of anaemia with H. pylori infection. We hypothesize that the poor bioavailability of iron in these countries could be related to H. pylori -induced low gastric acid output and we propose to investigate the role of H. pylori infection as a cause of anemia and treatment failure of iron supplementation in Bangladesh. A prospective, randomized, double-blind, placebo-controlled field trial is proposed among four groups ( 65 each) of H. Pylori infected children of 2-5 years of age with iron deficiency anemia. The children will be assigned to one of the four therapies: antibiotics alone (for H. Pylori eradication), antibiotic plus iron therapy, iron therapy alone, or placebo. Hemoglobin concentration, serum ferritin concentration, and transferrin receptor will be measured before and at 1 and 3 month after the intervention. We also propose a complementary study in an additional 20 children with H. Pylori infection and iron deficiency anemia to assess iron absorption with application of double stable isotopes. The change in hematological parameters will also be compared among the groups before and after the therapy. The results of this study are expected to have implications in the prevention and treatment of iron deficiency anemia in developing countries. |
| NCT00626262 ↗ | Open, Randomized, Two Way Crossover Study Comparing the Effect of Esomeprazole Adminstered Orally and iv | Completed | AstraZeneca | Phase 4 | 2002-07-01 | The purpose of this study is to examine the effects of Nexium at a dose of 20mg administered orally compared to intravenously on the maximum acid output in subjects with symptoms of Gastroesophageal reflux disease (GERD). |
| NCT00629564 ↗ | An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflu | Completed | AstraZeneca | Phase 4 | 2002-09-01 | This study looks at the effect on basal and pentagastrin-stimulated acid output of 40 mg Esomeprazole (Nexium) administered orally and intravenously as a 15-minute infusion to people with symptoms of Gastroesophageal Reflux Disease (GERD) |
| NCT00635414 ↗ | Open, Randomized, Two Way Crossover 40mg, Orally and Intravenously | Completed | AstraZeneca | Phase 4 | 2002-08-01 | This study looks at the effect on basal and pentagastrin-stimulated acid output of 40 mg Esomeprazole (Nexium) administered orally and intravenously as a 15-minute infusion to people with symptoms of Gastroesophageal Reflux Disease (GERD) |
| NCT01447849 ↗ | Lubiprostone and Mucus Secretion in Patients With Chronic Constipation | Completed | Texas Tech University Health Sciences Center, El Paso | Phase 2/Phase 3 | 2011-08-01 | The investigators hypothesize that the symptoms of chronic constipation in some patients are developed due to diminished production and secretion of the alimentary tract mucus resulting in poor lubrication. Therefore, the investigators assume that administration of lubiprostone may restore this lubrication impairment by stimulation of mucus production and secretion within the gastrointestinal tract. |
| NCT01538784 ↗ | Safety, Tolerability and Pharmacokinetics of Single Rising Doses of YF476, a Gastrin Antagonist, in Healthy Men | Completed | Ferring Pharmaceuticals | Phase 1 | 1996-05-01 | The objectives of the study were: - To assess the safety, tolerability and pharmacokinetics of YF476 in healthy volunteers. - To select a dose or doses of YF476 for detailed pharmacodynamic studies in healthy volunteers. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for PENTAGASTRIN
Condition Name
Clinical Trial Locations for PENTAGASTRIN
Trials by Country
Clinical Trial Progress for PENTAGASTRIN
Clinical Trial Phase
Clinical Trial Sponsors for PENTAGASTRIN
Sponsor Name
